Comparative Pharmacology
Head-to-head clinical analysis: MYCIFRADIN versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCIFRADIN versus SATRIC.
MYCIFRADIN vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic
Antiprotozoal, Antibiotic